218 related articles for article (PubMed ID: 16121685)
21. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.
Van Voorhis WC; Rivas KL; Bendale P; Nallan L; Hornéy C; Barrett LK; Bauer KD; Smart BP; Ankala S; Hucke O; Verlinde CL; Chakrabarti D; Strickland C; Yokoyama K; Buckner FS; Hamilton AD; Williams DK; Lombardo LJ; Floyd D; Gelb MH
Antimicrob Agents Chemother; 2007 Oct; 51(10):3659-71. PubMed ID: 17606674
[TBL] [Abstract][Full Text] [Related]
22. Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness.
Smith TK; Crossman A; Brimacombe JS; Ferguson MA
EMBO J; 2004 Nov; 23(23):4701-8. PubMed ID: 15526036
[TBL] [Abstract][Full Text] [Related]
23. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis.
Heby O; Persson L; Rentala M
Amino Acids; 2007 Aug; 33(2):359-66. PubMed ID: 17610127
[TBL] [Abstract][Full Text] [Related]
24. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo.
Wiesner J; Kettler K; Sakowski J; Ortmann R; Katzin AM; Kimura EA; Silber K; Klebe G; Jomaa H; Schlitzer M
Angew Chem Int Ed Engl; 2004 Jan; 43(2):251-4. PubMed ID: 14695623
[No Abstract] [Full Text] [Related]
25. Cell Cycle Inhibition To Treat Sleeping Sickness.
Epting CL; Emmer BT; Du NY; Taylor JM; Makanji MY; Olson CL; Engman DM
mBio; 2017 Sep; 8(5):. PubMed ID: 28928213
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity.
Wiesner J; Ortmann R; Mitsch A; Wissner P; Sattler I; Jomaa H; Schlitzer M
Pharmazie; 2003 Apr; 58(4):289-90. PubMed ID: 12749417
[No Abstract] [Full Text] [Related]
27. Geranylgeranyl diphosphate synthase: an emerging therapeutic target.
Wiemer AJ; Wiemer DF; Hohl RJ
Clin Pharmacol Ther; 2011 Dec; 90(6):804-12. PubMed ID: 22048229
[TBL] [Abstract][Full Text] [Related]
28. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug.
Huang TL; Bacchi CJ; Kode NR; Zhang Q; Wang G; Yartlet N; Rattendi D; Londono I; Mazumder L; Vanden Eynde JJ; Mayence A; Donkor IO
Int J Antimicrob Agents; 2007 Dec; 30(6):555-61. PubMed ID: 17920820
[TBL] [Abstract][Full Text] [Related]
29. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
30. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes.
de Koning HP
Trends Parasitol; 2008 Aug; 24(8):345-9. PubMed ID: 18599351
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of azasterols as anti-parasitics.
Gros L; Lorente SO; Jimenez CJ; Yardley V; Rattray L; Wharton H; Little S; Croft SL; Ruiz-Perez LM; Gonzalez-Pacanowska D; Gilbert IH
J Med Chem; 2006 Oct; 49(20):6094-103. PubMed ID: 17004723
[TBL] [Abstract][Full Text] [Related]
32. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum.
Chakrabarti D; Da Silva T; Barger J; Paquette S; Patel H; Patterson S; Allen CM
J Biol Chem; 2002 Nov; 277(44):42066-73. PubMed ID: 12194969
[TBL] [Abstract][Full Text] [Related]
33. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
[TBL] [Abstract][Full Text] [Related]
34. The effect of TAO expression on PCD-like phenomenon development and drug resistance in Trypanosoma brucei.
Tsuda A; Witola WH; Konnai S; Ohashi K; Onuma M
Parasitol Int; 2006 Jun; 55(2):135-42. PubMed ID: 16516538
[TBL] [Abstract][Full Text] [Related]
35. New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives.
Toriizuka Y; Kinoshita E; Kogure N; Kitajima M; Ishiyama A; Otoguro K; Yamada H; Omura S; Takayama H
Bioorg Med Chem; 2008 Dec; 16(24):10182-9. PubMed ID: 19013823
[TBL] [Abstract][Full Text] [Related]
36. In vitro trypanocidal activity of the anti-helminthic drug niclosamide.
Merschjohann K; Steverding D
Exp Parasitol; 2008 Apr; 118(4):637-40. PubMed ID: 18226810
[TBL] [Abstract][Full Text] [Related]
37. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a PRL protein tyrosine phosphatase from Plasmodium falciparum.
Pendyala PR; Ayong L; Eatrides J; Schreiber M; Pham C; Chakrabarti R; Fidock DA; Allen CM; Chakrabarti D
Mol Biochem Parasitol; 2008 Mar; 158(1):1-10. PubMed ID: 18096253
[TBL] [Abstract][Full Text] [Related]
39. Targeting of toxic compounds to the trypanosome's interior.
Barrett MP; Gilbert IH
Adv Parasitol; 2006; 63():125-83. PubMed ID: 17134653
[TBL] [Abstract][Full Text] [Related]
40. Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis.
Werbovetz KA
Curr Med Chem; 2000 Aug; 7(8):835-60. PubMed ID: 10828290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
